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Abstract
Background: Burkitt lymphoma (BL) is an aggressive B-cell lymphoma, with a characteristic clinical presentation, morphology
and immunophenotype. Over the past years, the typical translocation t(8;14) and its variants have been considered the
molecular hallmarkof this tumor. However, BL cases with no detectable MYCrearrangement havebeen identified.Intriguingly,
these cases express MYC at levels comparable with cases carrying the translocation. In normal cells c-Myc expression is tightly
regulated through a complex feedback loop mechanism. In cancer, MYC is often dysregulated, commonly due to genomic
abnormalities. It has recently emerged that this phenomenon may rely on an alteration of post-transcriptional regulation
mediated by microRNAs (miRNAs), whose functional alterations are associated with neoplastic transformation. It is also
emerging that c-Myc modulates miRNA expression, revealing an intriguing crosstalk between c-Myc and miRNAs.
Principal Findings: Here, we investigated the expression of miRNAs possibly regulated by c-Myc in BL cases positive or
negative for the translocation. A common trend of miRNA expression, with the exception of hsa-miR-9*, was observed in all
of the cases. Intriguingly, down-regulation of this miRNA seems to specifically identify a particular subset of BL cases, lacking
MYC translocation. Here, we provided evidence that hsa-miR-9-1 gene is heavily methylated in those cases. Finally, we
showed that hsa-miR-9* is able to modulate E2F1 and c-Myc expression.
Conclusions: Particularly, this study identifies hsa-miR-9* as potentially relevant for malignant transformation in BL cases
with no detectable MYC translocation. Deregulation of hsa-miR-9* may therefore be useful as a diagnostic tool, suggesting it
as a promising novel candidate for tumor cell marker.
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Introduction
The c-Myc transcription factor is pathologically activated in
many human malignancies [1]. A paradigm for c-Myc deregulation
is offered by Burkitt Lymphoma (BL), where chromosomal
translocations that join MYC with immunoglobulin (Ig) heavy-
(Igh) or light-chain (Igk,I g l) loci are the crucial initiating oncogenic
events [2]. High levels of c-MYC have been clearly shown to have a
tumour-promoting effect [3]. Just a 2-fold difference in c-Myc
expression can affect cell size in flies or cell number in mice [4–7].
However, there is increasing evidence that less than 10% of
classical BL cases lack an identifiable MYC rearrangement [8–10].
Interestingly, no significant difference of MYC expression between
MYC translocation-positive and negative cases has been found,
independently of genomic alterations [10]. This may suggest that
additional mechanisms, alternative to chromosomal translocations,
which may result in MYC deregulation also exist. c-Myc expression
is strictly regulated by a feedback loop autoregulatory mechanism
involving the transcription factor E2F1, whose loss impairs MYC-
mediated proliferation and lymphomagenesis [11]. c-Myc expres-
sion can be also regulated at the level of post-transcriptional control
from a new class of non-coding RNA, miRNAs, able to inhibit
mRNAs from being translated or causing them to be degraded [12].
MiRNAs play major roles in crucial processes as proliferation,
differentiation and cell death [13]. It has become clear that
alterations in the expression of miRNAs contribute to the
pathogenesis of most, if not all, human malignancies [14]. MiRNA
deregulation can be caused by various mechanisms, either genetic
or epigenetic, including deletions, amplifications or mutations
involving miRNA loci, epigenetic silencing or deregulation of
transcription factors that target specific miRNAs [14].
In a previous study, we have analyzed a set of BL cases lacking
MYC translocation, in which no other genomic aberrations, as
increase of MYC copy number or aneuploidy were present, which
showed high levels of MYC expression. We searched for alternative
molecular alterations responsible for c-MYC deregulation in these
cases and observed an altered expression of a specific miRNA, hsa-
mir-34b, predicted to regulate MYC [10]. Being MYC a specific
target of this miRNA, its deregulation may explain MYC altered
expression in these cases [10].
However, recent literature reports that c-Myc itself is in turn
able to activate the expression of several miRNAs [15–18] In
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miR-17-92 cluster, reported in literature as activated by c-Myc
[15,16]. In addition, the expression of both the functional strands
39-end (miR-9) and 59-end (miR9*) of the miRNA hsa-miR-9* has
been recently described to be induced by c-Myc [17,18].
In this study, we aimed at analyzing the expression of these specific
miRNAs regulated by c-Myc in the previously described set of BL
cases, based on the existence of a regulatory loop linking c-Myc and
specificmiRNAs.OurresultsshowthatasinglemiRNA,hsa-miR-9*,
was found differentially expressed between BL cases carrying or not
MYC translocation, being significantly down-regulated only in MYC
translocation-negative cases. Intriguingly, we provide evidence that
hsa-miR-9* is able to modulate E2F1 and c-Myc expression,
suggesting down-regulation of hsa-miR-9* as a possible mechanism
of c-Myc over-expression in BL cases negative for the translocation.
In summary, a better knowledge of miRNA alteration in such
cases can potentially provide new markers to improve diagnosis and
prognosis, as well as novel therapeutic approaches forBL treatment.
Materials and Methods
Ethics Statement
Ethics approval for this study was obtained from the Institu-
tional Review Board at the University of Siena, University of
Nairoby and at the CNIO. Informed written consent was obtained
in all cases.
Cases selection and Immunophenotype
For this study BL specimens collected at the Department of
Pathology, Nairobi Hospital, Kenya and the Department of
Human Pathology and Oncology, University of Siena, Italy, with
available remaining materials from our prior study, have been
used [10]. Since MYC translocation- negative BL cases may
represent a challenging diagnosis to discriminate them from
DLBCL and Intermediate DLBCL/BL, additional formalin-fixed
and paraffin-embedded (FFPE) specimens of MYC translocation-
negative Diffuse Large B cell Lymphoma (DLBCL), Intermediate
DLBCL/BL and BLs have been retrieved at the Department of
Human Pathology and Oncology, University of Siena, Italy, at the
Molecular Pathology Programme, CNIO, Spain and at the Aga
Khan University, Nairobi, Kenya. Attention was given to select
cases with immunophenotype suggestive of BL (CD10+, BCL6+,
BCL2- or weakly positive). Cases were reviewed by expert
pathologists (BC, LL) and diagnoses were confirmed by morphol-
ogy on histological slides stained with HE, Giemsa and by
immunophenotyping, according to the Word Health Organization
(WHO) classification which reports that MYC translocation-
negative BL cases must be otherwise completely typical to make
a diagnosis of BL [19].
Immunohistochemical studies were performed on representative
paraffin sections from each case using microwave pre-treatment of
slides for antigen retrieval. A large panel of antibodies recognizing
formalin-resistant epitopes of the various antigens was applied, in
conjunction with the alkaline phosphatase antialkaline phospha-
tase (APAAP) method, to visualize antibody binding [20]. Reactive
lymph nodes were used as a control.
The presence of the Epstein-Barr virus (EBV) was assessed by in
situ hybridization for EBERs using Epstein-Barr Virus (EBER)
PNA/Fluorescein (DAKO, Denmark), a mixture of PNA probes
complementary to the two nuclear EBER RNAs encoded by EBV,
in conjunction with DAKO PNA ISH Detection Kit (DAKO,
Denmark). Five micrometer-thick paraffin sections were depar-
affinized, rehydrated and processed according to manufacturer’s
instructions. A control slide, prepared from a paraffin-embedded
tissue block containing metastatic nasopharyngeal carcinoma in a
lymph node, accompanied each hybridization run.
Fluorescence in situ hybridization (FISH)
FISH analysis was performed following standard protocols used
during EUROFISH and available at www.euro-fish.org. All
reagents, instruments and split-signal probes were kindly provided
by DakoCytomation (Glostrup, Denmark). Briefly, MYC rearran-
gements were sought using the MYC FISH DNA Probe-Split
Signal using standard procedures. FISH was carried out as
previously reported [10]. Dual color fluorescent in situ hybridiza-
tion (FISH) for the MYC gene and the chromosome 8 centromere
(CEN8), interpretation of results, classification of increased or not
increased MYC gene copy number was carried out as previously
described [10].
Computational analysis
Messenger RNAs (mRNAs) predicted to be target of hsa-miR-9*
were identified by computational analysis, using web-available
resources (Mirnaviewer, PicTar, Tarbase [21] and miRBase [22];
mirnaviewer is available at http://cbio.mskcc.org/mirnaviewer; Pic-
Tar is a project of the Rajewsky lab at NYU’s Center for Compara-
tive Functional Genomics and the Max Delbruck Centrum, Berlin).
MiRNA extraction
FFPE sections of primary tumors and reactive lymph nodes as a
control were treated with Xylene to eliminate paraffin and then
miRNAs were extracted using TRIZOL (Invitrogen, Milan, Italy).
Germinal centre cells were isolated by laser capture microdissec-
tion and miRNAs were then extracted using TRIZOL. DNase I
(Promega, Milan, Italy) treatment was performed in all samples.
Analysis of miRNA expression
MiRNA expression was analyzed by qRT-PCR. Briefly, RNA
samples were reverse transcribed using the Taqman MicroRNA
reverse transcription kit (Applied Biosystems, Applera, Italy) and
primers specific for each miRNA (hsa-miR-17-5p, hsa-miR-20a,
hsa-miR-9, hsa-miR-9*), according to manufacturer’s instructions.
For each sample, 10 ng of total RNA were reverse transcribed.
Real-time PCR was performed using Taqman probes specific for
each miRNA and for RNU43, used as an endogenous control
(Applied Biosystems, Applera, Italy). Amount and quality of RNA
were evaluated measuring the OD at 260 nm, the 260/230 and
the 260/280 ratios by Nanodrop (Celbio, Italy). Quality of RNA
was also checked by BioAnalyzer (Agilent, CA).
Gene expression analysis
Relative quantificationofgene expression for E2F1 and MYCwas
also carried out by Real-time PCR using FluoCycle SYBR green
(Euroclone, Celbio, Italy) according to manufacturer’s instructions.
HPRT was used as housekeeping gene. Primer sequences for MYC
amplified a region of 129 bp: LEFT: AGCGACTCTGAGGAG-
GAAC; RIGHT: TGTGAGGAGGTTTGCTGTG. Primer se-
quences for E2F1 amplified a region of 136 bp: LEFT: GCC-
CTGAGGAGACCGTAG; RIGHT: ACAACAGCGGTTCTT-
GCTC. Primer sequences for HPRT amplified a region of 191 bp:
LEFT: AGCCAGACTTTGTTGGATTTG; RIGHT: TTTAC-
TGGCGATGTCAATAAG. Differences in gene expression were
calculated using the DDCt method [23].
Cell lines and nucleofection
A human B lymphoblastoid cell line (LCL) was used to perform
the in vitro experiments. Briefly, cells were cultured in RPMI
miRNA Deregulation in BL
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streptomycin, with 5% CO2,a t3 7 uC. Transient transfections
were performed by nucleofection, using an Amaxa apparatus,
program A23 and solution V (Amaxa, Cologne, Germany). A
transfection efficiency of 45% was obtained, as assessed by FACS
analysis for a GFP reporter. Cells (2610
6) were transfected with
10 nM, 25 nM and 50 nM of hsa-mir-9* mimic (C-300115-04-
0005, Dharmacon, Celbio, Italy), 50 nM miRNA inhibitor
Table 1. Clinical and pathological data of the different categories of analysed lymphoma.
MYC+ BL MYC- BL DLBCL GC-like Intermediate DLBCL/BL
Age range, y (median) 2–38 (14) 6–77 (17) 20–90 (49) 30–75 (31)
Sex F/M 3/7 3/6 6/4 2/4
Site (nodal/extranodal) 7/3 3/6 5/5 2/4
EBV+/total 5/10 1/9 0/10 0/6
HIV+/total 0/10 0/9 0/10 2/6
MYC translocation + 222
Total 10 9 10 6
doi:10.1371/journal.pone.0012960.t001
Figure 1. hsa-miR-9* and E2F1 expression in primary MYC translocation-positive and negative BL cases. (A) Expression of hsa-miR-
9* in primary MYC translocation-positive and negative BL cases. Reactive lymph nodes and germinal centre cells (C); BL cases positive for
MYC translocation [1–10]; BL cases negative for MYC translocation [11–19]; Relative expression of hsa-miR-9* was evaluated by qRT-PCR. BL cases
positive for MYC translocation showed hsa-miR-9* up-regulated, whereas it was down-regulated in MYC translocation-negative ones, except for one
case. (B) Expression of E2F1 in primary MYC translocation-positive and negative BL cases. Reactive lymph nodes and germinal centre cells
(C); BL cases positive for MYC translocation [1–10]; BL cases negative for MYC translocation [11–19]; Relative expression by qRT-PCR for E2F1 in
primary cases showed an up-regulation of E2F1 mRNA expression only in BL cases negative for MYC translocation. In all of the other cases, E2F1
mRNA levels were lower or comparable to control. Differences in gene expression were calculated using the DDCt method. Results are representative
of three different experiments. Error bars represent standard deviation between triplicates.
doi:10.1371/journal.pone.0012960.g001
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negative controls (NC I: IN-001000-01, NC: CN-001000-01,
Dharmacon, Celbio, Italy). RNA was extracted 24 hours after
nucleofection and hsa-miR-9* expression was checked by Real-
Time RT-PCR, as previously described. Probes for qRT-PCR
recognize both endogenus and transfected hsa-mir-9*.
Western blotting
Cell pellets of LCLs, untransfected or transfected with either
hsa-miR-9* 50 nM, its inhibitor or their respective negative
controls, NC and I NC, were lysed in EBC buffer (50 mM Tris-
HCl pH 8.0, NaCl 120 mM, 0,5% NP-40 and fresh protease
inhibitors). Western blotting (WB) was performed with anti-E2F1
([1:200], KH95, sc-251, Santa Cruz), anti-c-Myc ([1:200], 9E10,
sc-40 Santa Cruz) and anti-actin ([1:500], clone AC-40, #A-4700,
Sigma Aldrich, Milan, Italy) using the ECL (Pierce, Rockford),
following manufacturer’s instructions.
DNA extraction and BSP
FFPE section (10 mM) of 8 cases of endemic BL, negative for
MYC translocation, and two reactive lymph nodes were depar-
affinized with Xylene and DNA extraction was performed with
NucleoSpin kit (Macherey-Nagel), according to manufacturer’s
instructions.
Amount and quality of DNA were evaluated measuring the OD
at 260 nm, the 260/230 and the 260/280 ratios by Nanodrop
(Celbio, Italy). DNA quality control PCR was also performed as
previously described [24]. 1 mg of DNA of 7 cases was modified by
bisulfite (Chemicon kit) for 15 hours as previously reported [25].
Approximately 100 ng of converted DNA were amplified using
Figure 2. Expression of hsa-miR-9* and E2F1 in primary DLBCL and DLBCL/BL Intermediate cases in comparison with MYC
translocation-negative cases. (A) Expression of hsa-miR-9* in primary DLBCL and DLBCL/BL Intermediate cases in comparison with
MYC translocation-negative cases. DLBCL cases [1–10]; DLBCL/BL Intermediate cases negative for MYC translocation [11–16]; BL cases negative
for MYC translocation [17–25]. Relative expression of hsa-miR-9* was evaluated by qRT-PCR. All of DLBCL cases showed hsa-miR-9* over-expression, in
comparison with MYC translocation-negative BL cases. Intermediate DLBCL/BL cases showed an heterogeneous expression of hsa-miR-9*.
(B) Expression of E2F1 in primary DLBCL and DLBCL/BL Intermediate cases in comparison with MYC translocation-BL negative
cases. DLBCL cases [1–10]; DLBCL/BL Intermediate cases negative for MYC translocation [11–16]; BL cases negative for MYC translocation [17–25].
Relative expression of E2F1 was evaluated by qRT-PCR. E2F1 resulted less expressed in DLBCL cases, in comparison with MYC translocation-negative
BL cases. Intermediate DLBCL/BL cases showed an heterogeneous expression of E2F1. Differences in gene expression were calculated using the DDCt
method. Results are representative of three different experiments. Error bars represent standard deviation between triplicates.
doi:10.1371/journal.pone.0012960.g002
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their recognition sequence) for bisulfite sequencing as reported [26].
PCR products were separated on a 2% agarose gel to confirm
size, quantity and purity of each product, and then purified using
NucleoSpin Kit (Macherey-Nagel), according to manufacturer’s
instructions. 2 ml aliquot of purified PCR products were cycle
sequenced using Big Dye Terminator Mix (Applied Biosystem,
Foster City, CA) in a total volume of 20 ml. Reaction products
were purified with ethanol/MgCl2 and finally 5 ml of product were
resuspended in 15 ml of ultra pure water before being loaded on
ABI capillary sequencer. Sequence reads were base-called using
Chromas program. To explore in silico bisulfite modified DNA
(either or not methylated at its CpG dinucleotides) methBLAST
was used (http://medgen.ugent.be/methBLAST/), a sequence
similarity search program.
Results
Clinical, morphological features and immunophenotype
BL,DLBCLand IntermediateBL/DLBCLcaseswerediagnosed
based on morphology, immunophenotype and genetic alterations,
in accordance to the WHO classification [19]. The clinical and
pathological data of these cases are summarized in the Table 1.
c-Myc-induced miRNAs: hsa-miR-17-5p, hsa-miR-20a, hsa-
miR-9 and hsa-miR-9*
The expression of hsa-miR-17-5p, hsa-miR-20a, hsa-miR-9 and
hsa-miR-9*, reported to be regulated by c-Myc, was checked in all
of BL cases. As expected, a strong up-regulation of hsa-miR-17-5p
and hsa-miR-20a was found in all of the cases, independently of
MYC translocation, which is in line with high expression of MYC in
these cases (data not shown). Hsa-miR-9 showed an heterogeneous
expression among all of BL cases, with no significant difference
between MYC translocation-positive and negative BL cases (data
not shown).
Interestingly, the expression of hsa-miR-9* was significantly
different between MYC translocation-positive and negative cases,
compared to normal controls (reactive lymph nodes and GC cells),
being over-expressed in cases carrying MYC translocation (10/10)
and strongly down-regulated in the others (8/9) (Figure 1A).
Of note, one case negative for the translocation expressed hsa-
miR-9* at high levels. It is worth noting that among the cases
lacking MYC translocation, this was the only case positive for EBV,
and occurred in an elderly patient (Figure 1A).
The absence of MYC translocation in BL cases may represent a
challenge in the diagnosis of BL, to discriminate them from
DLBCL and cases with intermediate features between DLBCL
and BL cases (DLBCL/BL). To further confirm a role of hsa-miR-
9* as a possible molecular marker for MYC translocation-negative
BL, we tested its expression in DLBCL GC-like and Intermediate
DLBCL/BL MYC translocation-negative cases. Hsa-miR-9*
resulted over-expressed in all of DLBCL cases (10/10). As
expected, Intermediate DLBCL/BL cases showed an heteroge-
neous expression of hsa-miR-9*. In particular, hsa-miR-9* was
over-expressed in 4/6 cases, whereas 2/6 showed low expression,
similarly to BL cases lacking MYC translocation (Figure 2A).
Table 2. Summary of miRNA analysis in the different categories of analysed lymphoma.
MYC+ BL MYC- BL DLBCL GC-like Intermediate DLBCL/BL
MYC translocation + 22 2
Hsa-miR-9* expression level (median fold changes) High (5.57) Low (0.352) High (31.6) High/Low (47.3/0.25)
E2F1 expression level (median fold changes) Medium (0.78) High (1.74) Medium (0.5) Medium/High (0.78/3.02)
Total 10 9 10 6
The median fold changes has been used as an indicator of the expression level in each category of lymphomas. To group the median fold changes, cut-offs have been
defined as low (median fold changes ,0.5), medium (median fold changes between 0.5 and 1.5), and high (median fold changes .1.5) expression level.
doi:10.1371/journal.pone.0012960.t002
Figure 3. Computational analysis of E2F1 binding to hsa-miR-9*. Alignment of the predicted hsa-miR-9* target site in the E2F1 39-UTR from
several different species as predicted by PicTar. Shaded boxes indicate bases pairing with hsa-miR-9*. On the bottom of the figure the structure of
predicted duplex in human specie has been reported.
doi:10.1371/journal.pone.0012960.g003
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We then investigated the molecular mechanism underlying such
a difference in hsa-miR-9* expression. Using valid on-line
database, we searched for mRNAs predicted to be hsa-miR-9*
targets. Among those predicted, we found E2F1 as a possible
intriguing candidate, because it is known to controls c-Myc
expression [27,28]. First, we tested its expression in MYC
translocation-negative BL cases in comparison to BL carrying
Figure 4. Functional in vitro study on hsa-miR-9*. (A) Relative expression by qRT-PCR of hsa-mir-9* in LCL transfected with
increasing amounts of a synthetic hsa-mir-9*, compared to non-treated LCL and LCL transfected with a negative control (NC). The level of hsa-
mir-9* increased in a dose-dependent manner. (B) Relative expression by qRT-PCR of hsa-mir-9* in LCL transfected with an hsa-miR-9*
inhibitor, at the concentration of 50 nM, compared to non-treated LCL and LCL trasfected with a negative control (I NC). The level of hsa-mir-9*
decreased significantly upon transfection of the inhibitor. (C) Relative quantification of E2F1 and MYC transcripts after transfection of
increasing amounts of a synthetic hsa-mir-9*. A dose-dependent decrease of both genes is detected in the presence of synthetic hsa-mir-9*.
(D) Relative quantification of E2F1 and MYC transcripts after transfection of a hsa-mir-9* inhibitor. Transfection of the hsa-mir-9*
inhibitor is able to increase E2F1 and MYC expression, in comparison with the expression level of both proteins in non-treated LCL or cells transfected
with a negative control (I NC). (E) E2F1 and c-Myc protein levels in LCL transfected with higher concentration of synthetic hsa-mir-9*,
hsa-mir-9* inhibitor and their negative controls, evaluated by western blotting. Lane 1: non-treated LCL; lane 2: LCL transfected with NC,
lane 3: LCL transfected with 50 nM synthetic hsa-mir-9*, lane 4: LCL transfected with I NC; lane 5: LCL transfected with 50 nM hsa-mir-9* inhibitor.
Figure is representative of three different experiments. Numbers on top indicate densitometric analysis.
doi:10.1371/journal.pone.0012960.g004
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GC cells). E2F1 was up-regulated only in BL cases lacking MYC
translocation, in respect with both BL cases carrying MYC
translocation and normal controls (Figure 1B). To further confirm
these results, we tested its expression also in DLBCL and
Intermediate DLBCL/BL cases (Figure 2B), where an inverse
correlation between hsa-miR-9* and E2F1 was also found. Table 2
summarizes the level of the expression of hsa-miR-9* and E2F1
with the presence or not of MYC translocation in the different
categories of analysed lymphomas.
E2F1 over-expression observed in MYC translocation-negative
BL cases could be responsible for c-Myc over-expression, and to
sustain it at high levels in the absence of translocation. This event
may be relevant for malignant transformation, because of the
reciprocal activation E2F1/c-Myc.
Functional in vitro study on hsa-miR-9*
To confirm the bioinformatic predictions which indicate E2F1
as a possible target of hsa-miR-9* (Figure 3), we transfected a
synthetic hsa-mir-9* (Figure 4A) or its inhibitor (Figure 4B) in a
human B lymphoblastoid cell line, and then measured E2F1
expression both at the mRNA and protein levels by qRT-PCR
and western blotting, respectively. We found a significant dose-
dependent decrease in E2F1 mRNA in cells transfected with hsa-
mir-9* (Figure 4C). Conversely, when a hsa-mir-9* inhibitor was
transfected, an increase in E2F1 mRNA was observed (Figure 4D).
As c-Myc expression can be induced by E2F1, we also checkedMYC
mRNA expression. Accordingly, MYC mRNA levels resulted down-
regulated after transfection of a synthetic hsa-miR-9* (Figure 4C). On
the other hand, we observed an increase of MYC mRNA expression
after silencing of hsa-miR-9* (Figure 4D).These findings were
confirmed at the protein level, by western blotting (Figure 4E).
Methylation analysis of hsa-miR-9-1 gene in primary
tumors
Hypermethylation is described as possible mechanism of
miRNA silencing. Due to the presence of a CpG island in hsa-
miR-9-1 gene (Ensemble Genome browser, ENSG00000207933),
we performed methylation analysis by bisulfite sequencing to assess
whether down-regulation of hsa-miR-9-1 in those cases could rely
on an epigenetic inactivation. Figure 5 shows the results, indicating
hypermethylation in BL cases negative for MYC translocation, in
respect with normal controls.
Discussion
The molecular feature of Burkitt lymphoma (BL) is the
translocation that places MYC under the control of immunoglo-
bulin gene regulatory elements. However, there is recent evidence
that infrequent cases may lack an identifiable MYC translocation,
the explanation for which is still uncertain, though suggesting the
existence of pathogenetic mechanisms alternative to genetic
alterations [8,9].
Recently, it has been suggested that the over-expression of MYC
in the absence of translocation might be due to miRNA
deregulation [10]. It has been recently demonstrated that hsa-
miR-34b is expressed at different instances between MYC
translocation-negative and positive BL cases [10]. In particular,
it is down-regulated only in MYC translocation-negative BL cases,
giving evidence that its deregulation could influence c-Myc
expression in the absence of genomic translocation. On the other
hand, c-Myc itself is able to activate the expression of specific
miRNAs [12–15], suggesting the existence of a feedback loop
between c-Myc and specific miRNAs, able to reciprocally control
their expression. It may then be speculated that c-Myc over-
expression induces a specific miRNA pattern that, in turn, might
be responsible for a differential gene expression, and for functional
alterations of tumor cells.
Here, we found a strong up-regulation of hsa-miR-17-5p and
hsa-miR-20a, which correlates with high levels of MYC expression
in these tumors, and is in line with the c-Myc-mediated induction
of the miR-17-92 cluster. An heterogeneous expression of hsa-
miR-9 was observed among BL cases, whereas hsa-miR-9* was the
only miRNA strongly down-regulated only in BL MYC transloca-
tion-negative cases, with the exception of one case. Interestingly,
this case was the only EBV-positive among the MYC translocation-
negative BL cases. It might be argued that the virus may be able to
modulate hsa-miR-9* expression in the absence of translocation,
being now clear the existence of a delicate and complex interplay
between viruses and cellular miRNAs [29–32].
The MYC translocation-negative BL cases may represent a
challenging diagnosis to discriminate them from DLBCL and from
cases with intermediate features between DLBCL and BL cases
(DLBCL/BL) [8,19,33,34]. The latter is an heterogeneous
category that is not considered a distinct disease entity, but it is
useful in allowing the classification of cases not meeting criteria for
classical BL or DLBCL. The diagnosis should not be made in cases
of morphologically typical DLBCL that have a MYC rearrange-
ment, or in otherwise typical BL in which a MYC rearrangement
cannot be demonstrated. Improvements in appropriate therapeu-
tic approaches should be established for this category which as
extremely poor prognosis.
To further confirm that the hsa-miR-9* may be considered
specific a molecular marker for BL cases lacking the typical
translocation, we tested its expression also in DLBCL and
Intermediate DLBCL/BL cases. We found that DLBCL cases
showed a strong over-expression of hsa-miR-9*, whereas
Intermediate DLBCL/BL cases an heterogeneous expression.
In fact, among the latter hsa-miR-9* was over-expressed in 4/6
and down-regulated in 2/6, similar to BL cases lacking MYC
translocation. These findings further suggest that Intermediate
DLBCL/BL cases are an heterogeneous category and additional
studies are necessary to demonstrate whether hsa-miR-9* may be
Figure 5. Methylation analysis of hsa-mir-9-1 gene in primary
tumors. Methylation density of hsa-mir-9-1 gene in endemic BL cases
negative for MYC translocation (NT, Negative for translocation) and
reactive lymph nodes (C1, C2) by bisulfite sequencing; Solid circles (N)
and empty circles (#) indicate that CpG site is methylated or
unmethylated, respectively. The BL cases negative for MYC translocation
showed aberrant (cases 1–5) and partial (cases 6 and 7) methylation, in
respect with the normal controls (C1 and C2). Cases NT1 and NT2
showed 21/23 CpG methylated, case NT3 22/23 CpGs methylated, cases
NT3 and NT4 showed all of CpGs methylated (23/23), case NT5 showed
12/23 CpG methylated and case NT6 showed 9/23 CpG methylated. On
the other hand, the normal controls (C1, C2) showed 2/23 and 1/23
CpGs methylated, respectively.
doi:10.1371/journal.pone.0012960.g005
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to identify cases that may benefit from a more aggressive
therapy.
To unravel the pathological role of hsa-miR-9* down-regulation
on MYC translocation-negative BL cases, we looked at mRNAs
predicted to be target of hsa-miR-9*. Among those predicted, we
found particularly interesting E2F1, which is essential for the G1-
S1 phase passage. Expression of E2F1 is known to be induced by
c-Myc, and in turn controls c-Myc expression [27,28].
Interestingly, an inverse correlation between hsa-miR-9* and
E2F1 was found. In particular, E2F1 over-expression observed in
BL cases lacking the typical translocation may represent itself an
appealing possible mechanism able to determine c-Myc over-
expression and sustain it at high levels in the absence of
translocation, due to the existence of a feedback loop responsible
for controlling the reciprocal expression of these transcription
factors. On the other hand, hsa-miR-9* up-regulation observed
both in MYC translocation-positive BL, DLBCL and in 4/6
Intermediate BL/DLBCL cases may be consistent with a
regulatory loop between hsa-miR-9* and E2F1. To verify our
hypothesis, based on bioinformatic predictions, functional in vitro
studies were performed. E2F1 regulation by hsa-miR-9* was
observed, either direct or indirect, as miR9* ectopic up-regulation
reduces E2F1 levels. Conversely, miR9* silencing induces E2F1
expression. As a consequence, also the expression of MYC was
affected, both at the mRNA and protein levels. These findings
highlight that hsa-miR-9* inactivation may determine E2F1 up-
regulation and consequent MYC over-expression in BL lacking
MYC translocation.
MiRNA silencing in cancer can be due to several mechanism,
as a consequence of genomic abnormalities or epigenetic
regulation [35]. Hsa-miR-9* down-regulation in MYC translo-
cation-negative cases is due to an epigenetic mechanism, as an
aberrant methylation of hsa-miR-9-1 gene was observed in
these cases. Accordingly, inactivation of hsa-miR-9-1 gene due
to hypermethylation has been suggested as an additional
mechanism for miRNA inactivation also in human breast
cancer [26].
Overall, we can conclude that several mechanisms may explain
MYC over-expression. In particular, miRNA deregulation may
have an important role in the pathogenesis of BL cases negative for
MYC translocation, and may provide a new intriguing molecular
mechanism other than typical translocation in affecting MYC
expression (Figure 6).
Hsa-miR-9* down-regulation seems to be specific for BL cases
lacking MYC translocation, and identifies hsa-miR-9* as a possible
novel candidate for a more accurate clinical diagnosis, helping to
design miRNA-based gene therapy, which could be the future tool
for gene therapy.
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